Evidence map›Paper›PMID 31623189›Full record

ArticleNutrients2019

Blood and Brain Biochemistry and Behaviour in NTBC and Dietary Treated Tyrosinemia Type 1 Mice.

Willem G van Ginkel, Danique van Vliet, Els van der Goot, Martijn H J R Faassen, Arndt Vogel, M Rebecca Heiner-Fokkema, Eddy A van der Zee, Francjan J van Spronsen

Open access · goldAbstract readComparative Study
In one paragraph

Article in Nutrients, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Treatment adherence in tyrosinemia type 1 patients.Orphanet journal of rare diseases · 2021
    Observational
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Willem G van GinkelBeatrix Children's Hospital, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands. w.g.van.ginkel@umcg.nl.
Danique van VlietBeatrix Children's Hospital, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands. d01.vliet@umcg.nl.
Els van der GootMolecular Neurobiology, Groningen Institute for Evolutionary Life Sciences, University of Groningen, 9747 AG Groningen, The Netherlands. e.van.der.goot@rug.nl.
Martijn H J R FaassenDepartment of Laboratory Medicine, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands. h.j.r.van.faassen@umcg.nl.
Arndt VogelDepartment of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, 30625 Hannover, Germany. Vogel.Arndt@mh-hannover.de.
M Rebecca Heiner-FokkemaDepartment of Laboratory Medicine, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands. m.r.heiner@umcg.nl.
Eddy A van der ZeeMolecular Neurobiology, Groningen Institute for Evolutionary Life Sciences, University of Groningen, 9747 AG Groningen, The Netherlands. e.a.van.der.zee@rug.nl.
Francjan J van SpronsenBeatrix Children's Hospital, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands. f.j.van.spronsen@umcg.nl.
University of Groningen · NLMedizinische Hochschule Hannover · DEUniversity Medical Center Groningen · NL

Funding

Stofwisselkracht .
6 · The paper itself

Abstract

Tyrosinemia type 1 (TT1) is a rare metabolic disease caused by a defect in the tyrosine degradation pathway. Neurocognitive deficiencies have been described in TT1 patients, that have, among others, been related to changes in plasma large neutral amino acids (LNAA) that could result in changes in brain LNAA and neurotransmitter concentrations. Therefore, this project aimed to investigate plasma and brain LNAA, brain neurotransmitter concentrations and behavior in C57 Bl/6 fumarylacetoacetate hydrolase deficient (FAH-/-) mice treated with 2-(2-nitro-4-trifluoromethylbenoyl)-1,3-cyclohexanedione (NTBC) and/or diet and wild-type mice. Plasma and brain tyrosine concentrations were clearly increased in all NTBC treated animals, even with diet (

Indexed as

Diet, Protein-RestrictedAmino Acids, NeutralAnimal FeedAnimalsBehavior, AnimalBiogenic MonoaminesBiomarkersBrainCyclohexanonesDisease Models, AnimalEnzyme InhibitorsFemaleHydrolasesHydroxyindoleacetic AcidMaleMice, Inbred C57BLAmino Acids, NeutralBiogenic MonoaminesBiomarkersCyclohexanonesEnzyme InhibitorsfumarylacetoacetaseHydrolasesHydroxyindoleacetic AcidnitisinoneNitrobenzoatesbrain biochemistryFAHlarge neutral amino acidsmiceNTBCphenylalaninetyrosinetyrosinemia type 1

Identifiers

PMID31623189
PMCPMC6836052
OpenAlexW2981245462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.